<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9">
  <url>
    <loc>https://www.biopharmawatch.com/news/TRAW/traws-pharma-q3-2026-financial-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T21:35:00.000Z</news:publication_date>
      <news:title>Traws Pharma Reports Third Quarter 2026 Financial Results and Provides Business Highlights</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/GRDN/guardian-pharmacy-services-citi-conference-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T21:30:00.000Z</news:publication_date>
      <news:title>Guardian Pharmacy Services, Inc. to Participate in Upcoming Citi Annual Global Healthcare Conference</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/POCI/precision-optics-q1-fiscal-2027-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T21:30:00.000Z</news:publication_date>
      <news:title>Precision Optics Reports First Quarter Fiscal 2027 Financial Results</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/OLMA/olema-oncology-participate-upcoming-investor-conferences-20261116</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T21:30:00.000Z</news:publication_date>
      <news:title>Olema Oncology to Participate in Upcoming Investor Conferences</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/AEON/aeon-biopharma-q3-2026-financial-results-update</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T21:15:00.000Z</news:publication_date>
      <news:title>AEON Biopharma Reports Third Quarter 2026 Financial Results and Provides Corporate Update</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/GNLX/genelux-corporation-q3-2026-financial-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T21:14:00.000Z</news:publication_date>
      <news:title>Genelux Corporation Reports Third Quarter Financial Results and Provides Business Updates</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/FBLG/fibrobiologics-q3-2026-financial-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T21:13:00.000Z</news:publication_date>
      <news:title>FibroBiologics Reports Third Quarter 2026 Financial Results; Highlights Upcoming Catalysts</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/BBNX/eversense-365-ilet-bionic-pancreas-launch</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T21:13:00.000Z</news:publication_date>
      <news:title>Senseonics and Beta Bionics Launch Eversense® 365 and iLet® Bionic Pancreas Integration</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/AYTU/rosemont-acquires-aytu-biopharma-expansion</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T21:11:00.000Z</news:publication_date>
      <news:title>Rosemont Pharmaceuticals to acquire Aytu BioPharma to accelerate US expansion</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/IMDX/insight-molecular-diagnostics-public-offering</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T21:10:00.000Z</news:publication_date>
      <news:title>Insight Molecular Diagnostics Announces Proposed Public Offering</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/GILD/gilead-expands-access-obeldesivir-ebola-bvd</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T21:05:00.000Z</news:publication_date>
      <news:title>Gilead Expands Access to Investigational Obeldesivir for Ebola Bundibugyo Virus Disease Through Voluntary Licensing</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/TXG/10x-genomics-collaborations-autoimmune-disease-research</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T21:05:00.000Z</news:publication_date>
      <news:title>10x Genomics Expands Global Research in Blood-Based Diagnostics for Autoimmune Disease with Two New Collaborations</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-successful-us-fda-type-c-meeting-phase</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T21:05:00.000Z</news:publication_date>
      <news:title>IDEAYA Biosciences Announces Successful US FDA Type C Meeting on Phase 2/3 Registrational Trial Designs to Support Potential Accelerated and Full Approval for IDE849, a Potential Best-in-Class DLL3 TOP1 ADC, in Neuroendocrine Carcinomas</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ACH/blue-shield-california-accendra-health-home-care</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T21:05:00.000Z</news:publication_date>
      <news:title>BLUE SHIELD OF CALIFORNIA EXPANDS COLLABORATION WITH ACCENDRA HEALTH TO IMPROVE ACCESS TO HOME-BASED CARE</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/NSPR/inspiremd-cguard-prime-veithsymposium-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T21:05:00.000Z</news:publication_date>
      <news:title>InspireMD Announces Talks Featuring CGuard and CGuard Prime at VEITHsymposium 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/KYNB/kyntra-bio-reports-third-quarter-2026-financial-results-provides-business</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T21:05:00.000Z</news:publication_date>
      <news:title>Kyntra Bio Reports Third Quarter 2026 Financial Results and Provides Business Update</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/GLAS/glass-house-brands-q3-2026-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T21:05:00.000Z</news:publication_date>
      <news:title>Glass House Brands Reports Third Quarter 2026 Financial Results</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-q3-2026-results-updates</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T21:05:00.000Z</news:publication_date>
      <news:title>ORIC® Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Operational and Rinzimetostat Program Updates</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/AIDX/2020-biolabs-q3-2026-financial-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T21:05:00.000Z</news:publication_date>
      <news:title>20/20 BioLabs Reports Third Quarter 2026 Financial Results and Recent Business Updates</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/LONA/leonabio-q3-2026-financial-results-update</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T21:05:00.000Z</news:publication_date>
      <news:title>LeonaBio Reports Third Quarter 2026 Financial Results and Provides Business Update</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/CNTB/connect-biopharma-reports-q3-2026-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T21:05:00.000Z</news:publication_date>
      <news:title>Connect Biopharma Reports Third Quarter 2026 Financial Results and Provides Business Update</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/OMER/omeros-corporation-q3-2026-financial-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T21:02:00.000Z</news:publication_date>
      <news:title>Omeros Corporation Reports Third Quarter 2026 Financial Results</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/CRVO/cervomed-neflamapimod-ctad-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T21:02:00.000Z</news:publication_date>
      <news:title>CervoMed Presents Interim Data at CTAD 2026 Showing Neflamapimod Reduces Neurodegeneration Biomarker in Nonfluent Variant Primary Progressive Aphasia</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-fiscal-results-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T21:01:00.000Z</news:publication_date>
      <news:title>Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-q3-2026-update</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T21:01:00.000Z</news:publication_date>
      <news:title>BrainStorm Cell Therapeutics Announces Third Quarter 2026 Financial Results and Provides Corporate Update</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/KROS/keros-therapeutics-announces-additional-5-million-share-repurchase-authorization</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T21:01:00.000Z</news:publication_date>
      <news:title>Keros Therapeutics Announces Additional $5 Million Share Repurchase Authorization</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/EBS/asymov-emergent-biosolutions-ebola-antibodies-partnership</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T21:01:00.000Z</news:publication_date>
      <news:title>Asimov and Emergent Biosolutions Announce Cell Line Development Partnership to Advance Novel Antibodies Against Ebola</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/CARL/carlsmed-participate-upcoming-investor-conferences</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T21:01:00.000Z</news:publication_date>
      <news:title>Carlsmed to Participate in Upcoming Investor Conferences</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/IDXG/interpace-biosciences-q3-2026-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T21:01:00.000Z</news:publication_date>
      <news:title>Interpace Biosciences Announces Third Quarter 2026 Financial and Business Results</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/WWB/windward-bio-ipo-251-million</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T21:01:00.000Z</news:publication_date>
      <news:title>Windward Bio Announces Closing of $251.2 Million Initial Public Offering and Concurrent Private Placement, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/XCUR/exicure-filing-notification-late-filing-form-12b-25</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T21:00:00.000Z</news:publication_date>
      <news:title>Exicure Announces Filing of Notification of Late Filing on Form 12b-25</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-obesityweek-2026-data</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T21:00:00.000Z</news:publication_date>
      <news:title>Rhythm Pharmaceuticals Announces Presentation of New Data at ObesityWeek® 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-nasdaq-listing-rule-5635-c-4-20261116</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T21:00:00.000Z</news:publication_date>
      <news:title>Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/PACS/pacs-group-presentation-stephens-conference-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T20:21:00.000Z</news:publication_date>
      <news:title>PACS Group, Inc. to Present at the Stephens Annual Investment Conference on November 19, 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/RVP/retractable-technologies-q3-2026-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T20:16:00.000Z</news:publication_date>
      <news:title>Retractable Technologies, Inc. Results for the Periods Ended September 30, 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/QTRX/quanterix-expands-alzheimers-testing-new-jersey</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T18:30:00.000Z</news:publication_date>
      <news:title>Quanterix Expands Access to Blood-Based Alzheimer&apos;s Testing in New Jersey and Surrounding Area Through Exclusive Partnership with Sherman Abrams Laboratory</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/NKGN/nkgen-biotech-reports-long-term-clinical-observations-investigational-alzheimer-s</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T18:05:00.000Z</news:publication_date>
      <news:title>NKGen Biotech Reports Long-Term Clinical Observations with Investigational Alzheimer’s Treatment Troculeucel at CTAD 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/RVMD/european-commission-approves-rasonque-daraxonrasib</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T18:00:00.000Z</news:publication_date>
      <news:title>European Commission Approves Revolution Medicines’ RASONQUE® (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/DH/definitive-healthcare-ai-growth-intelligence-platform</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T15:45:39.000Z</news:publication_date>
      <news:title>Healthcare Leaders Turn Months-Long Analyses Into Minutes With AI-Powered Growth Intelligence Platform</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/RHEP/regional-health-properties-q3-2026-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T14:35:00.000Z</news:publication_date>
      <news:title>Regional Health Properties Reports Third Quarter 2026 Results</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/RPID/rapid-micro-biosystems-q3-2026-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T14:28:00.000Z</news:publication_date>
      <news:title>Rapid Micro Biosystems Reports Third Quarter 2026 Financial Results</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/RPID/rapid-micro-biosystems-merck-acquisition</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T14:26:00.000Z</news:publication_date>
      <news:title>Rapid Micro Biosystems Signs Definitive Agreement to be Acquired by Merck KGaA, Darmstadt, Germany</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/QCLS/qc-technologies-optical-processing-unit-development</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T14:15:00.000Z</news:publication_date>
      <news:title>Q/C Technologies Reports Over $10 Million in Cash and Investments to Fund Development of Its Optical Processing Unit</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/DARE/dare-bioscience-additional-grant-funding</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T14:09:00.000Z</news:publication_date>
      <news:title>Daré Bioscience Receives Approximately $852,000 in Additional Grant Funding</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/IVF/invo-fertility-q3-2026-results-revenue-growth</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T14:08:00.000Z</news:publication_date>
      <news:title>INVO Fertility Reports Third Quarter 2026 Results Highlighting 28% Clinic Revenue Growth and Continued Positive Clinic-Level Adjusted EBITDA</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/MMED/fda-clears-minimed-fit-tubeless-insulin-pump</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T14:05:00.000Z</news:publication_date>
      <news:title>FDA Clears MiniMed Fit™ -- World&apos;s First and Only Tubeless Insulin Pump with Up to Seven-Day Wear and Zero Interruptions</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ACAD/acadia-exclusive-distribution-kyorin-daybue-japan</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T14:04:00.000Z</news:publication_date>
      <news:title>Acadia Pharmaceuticals Enters Exclusive Distribution Agreement with KYORIN Pharmaceutical for DAYBUE® STIX (trofinetide) in Japan</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/JAGX/jaguar-health-reports-q3-2026-financials</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T14:00:00.000Z</news:publication_date>
      <news:title>Jaguar Health Reports Third Quarter 2026 Financials</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/LNTH/lantheus-phase-3-tauklarify-alzheimers-imaging</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T14:00:00.000Z</news:publication_date>
      <news:title>Lantheus Presents Data from Two Pivotal Phase 3 Studies of TAUKLARIFY (Florquinitau F 18 Injection) PET Imaging in Early Alzheimer’s Disease</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/REVB/revelation-biosciences-gemini-development-plan</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T14:00:00.000Z</news:publication_date>
      <news:title>Revelation Biosciences Announces Accelerated Gemini Development Plan and Strategic Partnership Initiatives</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/VTRS/viatris-cadillac-f1-partnership-2027</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T14:00:00.000Z</news:publication_date>
      <news:title>CADILLAC FORMULA 1® TEAM WELCOMES VIATRIS AS OFFICIAL GLOBAL PHARMACEUTICAL PARTNER</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/OMDA/omada-health-ai-meal-feedback-glp1-outcomes-obesityweek-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T14:00:00.000Z</news:publication_date>
      <news:title>Omada Health Presents AI-Powered Meal Feedback Research and 12-Month GLP-1 Care Track Outcomes at ObesityWeek 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/EW/caregivers-role-heart-health-awareness</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T13:59:00.000Z</news:publication_date>
      <news:title>Edwards Lifesciences: WHEN IT COMES TO HEART HEALTH, CAREGIVERS CAN MAKE A DIFFERENCE</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/AIMD/ainos-reports-q3-2026-results-ai-nose-momentum</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T13:41:56.000Z</news:publication_date>
      <news:title>Ainos Reports Third Quarter 2026 Results and Highlights Expanding AI Nose Commercial Momentum</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/HIND/vyome-reports-reduction-q3-2026-loss-per-share</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T13:32:00.000Z</news:publication_date>
      <news:title>Vyome Reports Sharp Reduction in Q3 2026 Loss Per Share; Advances Lead VT-1953 Program</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-longevity-summit-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T13:32:00.000Z</news:publication_date>
      <news:title>Niagen Bioscience to Present at the Sixth Annual Longevity Summit Taking Place at the Buck Institute for Research on Aging</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/MTVA/metavia-da-1726-preclinical-data-obesityweek-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T13:31:00.000Z</news:publication_date>
      <news:title>MetaVia Presents Preclinical Data Supporting the Potential of DA-1726 to Address Liver Disease and Weight Loss at ObesityWeek® 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/PRE/prenetics-diplo-global-ambassador-partnership</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T13:30:19.000Z</news:publication_date>
      <news:title>Prenetics’ IM8 Announces Three-Time GRAMMY-Winning DJ and Producer Diplo as IM8 Global Ambassador and Shareholder in Multi-Year Partnership</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/APVO/aptevo-3q26-business-update-mipletamig</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T13:30:00.000Z</news:publication_date>
      <news:title>Aptevo Provides 3Q26 Business Update Highlighting Growing Momentum for Mipletamig and Reports Third Quarter Financial Results</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-meiji-seika-investment</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T13:30:00.000Z</news:publication_date>
      <news:title>Arcturus Therapeutics Announces $50 Million Investment by Meiji Seika Pharma as Part of Expanded Collaboration</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ACOG/alpha-cognition-benzgalantamine-patent-publication</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T13:30:00.000Z</news:publication_date>
      <news:title>Alpha Cognition Announces Publication of U.S. Patent Application for Benzgalantamine for Treating Persistent Post-Concussion Symptoms</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/CAI/caris-life-sciences-whole-transcriptome-sequencing-amp-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T13:30:00.000Z</news:publication_date>
      <news:title>Caris Life Sciences Presented Research Demonstrating the Value of Whole Transcriptome Sequencing in Precision Oncology at the Association of Molecular Pathology 2026 Annual Meeting</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/SCNX/scienture-q3-2026-results-revenue-growth</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T13:30:00.000Z</news:publication_date>
      <news:title>SCIENTURE Reports Q3 2026 Results with Approximately 265% Sequential Revenue Growth Driven by the Commercial Launch of REZENOPY™</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/AURX/nuo-therapeutics-q3-2026-financial-results-update</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T13:30:00.000Z</news:publication_date>
      <news:title>Nuo Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/MBOT/microbot-medical-q3-2026-operating-achievements</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T13:30:00.000Z</news:publication_date>
      <news:title>Microbot Medical® Files 10-Q and Highlights Key Third Quarter Operating Achievements</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/WWB/windward-bio-nasdaq-debut-shares-up-68</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T13:27:00.000Z</news:publication_date>
      <news:title>Windward Bio Lists on Nasdaq, Shares Up 68% on Debut</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/NVO/novo-nordisk-s-share-repurchase-programme-20261116</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T13:24:00.000Z</news:publication_date>
      <news:title>Novo Nordisk A/S - share repurchase programme</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/TRLV/trulieve-new-dispensary-tampa-florida</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T13:15:00.000Z</news:publication_date>
      <news:title>Trulieve to Open Medical Cannabis Dispensary in Tampa, Florida</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/HCWB/hcw-biologics-q3-2026-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T13:15:00.000Z</news:publication_date>
      <news:title>HCW Biologics Reports Third Quarter 2026 Business and Clinical Development Highlights and Financial Results</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/VIVS/vivosim-labs-namkind-liver-intestine-data-act-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T13:05:00.000Z</news:publication_date>
      <news:title>VivoSim Labs to Showcase Breakthrough Multiparametric NAMkind™ Liver and Intestine Data at the 2026 American College of Toxicology (ACT) Annual Meeting</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/XRTX/xortx-completes-manufacturing-clinical-drug-supply</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T13:05:00.000Z</news:publication_date>
      <news:title>XORTX Completes Manufacturing of Clinical Drug Supply</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ERAS/erasca-virtual-investor-event-phase-1-data</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T13:01:00.000Z</news:publication_date>
      <news:title>Erasca to Host Virtual Investor Event Highlighting Clinical Momentum Across Its RAS-Targeting Franchise</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/APMD/apnimed-reports-q3-2026-results-and-update</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T13:00:39.000Z</news:publication_date>
      <news:title>Apnimed Reports Third Quarter 2026 Financial Results and Provides Corporate Update</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/NTHI/neonc-ceo-amir-heshmatpour-share-purchases</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T13:00:36.000Z</news:publication_date>
      <news:title>NeOnc CEO Amir Heshmatpour’s 2026 Open-Market Share Purchases Exceed $1.5 Million</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/CGON/pivot-006-phase-3-trial-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T13:00:26.000Z</news:publication_date>
      <news:title>PIVOT-006 Phase 3 Registrational Trial Demonstrates Unprecedented Improvement in Recurrence-Free Survival (RFS) for Intermediate-Risk and High-Grade Ta Non-Muscle Invasive Bladder Cancer (NMIBC)</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/NATR/natures-sunshine-partnership-peter-nielsen</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T13:00:00.000Z</news:publication_date>
      <news:title>Nature’s Sunshine Announces Partnership with Health and Fitness Expert Peter Nielsen</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/CDRE/cadre-holdings-cfo-transition</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T13:00:00.000Z</news:publication_date>
      <news:title>Cadre Holdings Announces Chief Financial Officer Transition</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/RADX/radiopharm-theranostics-phase-2b-study-rad101</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T13:00:00.000Z</news:publication_date>
      <news:title>Radiopharm Theranostics Presents Interim Analysis from Phase 2b Imaging Study of RAD101 in Suspected Recurrent Brain Metastases Following Radiotherapy at the Society for Neuro-Oncology Annual Meeting</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/NSRX/nasus-pharma-appoints-nir-sassi-cfo</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T13:00:00.000Z</news:publication_date>
      <news:title>Nasus Pharma Appoints Nir Sassi as Chief Financial Officer</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/TEVA/fda-approves-igalmi-at-home-agitation-treatment</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T13:00:00.000Z</news:publication_date>
      <news:title>U.S. FDA Approves IGALMI® as First At-Home Acute Treatment for Agitation Associated with Schizophrenia, Schizoaffective Disorder, or Bipolar I or II Disorder in Adults</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/TBIO/telesis-bio-strategic-focus-ai-drug-discovery</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T13:00:00.000Z</news:publication_date>
      <news:title>Telesis Bio Announces Strategic Focus on AI-Native Drug Discovery and Launches New Website</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ESLA/estrella-immunopharma-artemis-t-cell-therapy-data-ash-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T13:00:00.000Z</news:publication_date>
      <news:title>Estrella Immunopharma Highlights ARTEMIS® T-Cell Therapy Data Selected for ASH 2026, Demonstrating Deep and Durable Leukemia Responses and Superior Extramedullary Disease Clearance Versus Conventional CAR-T in Preclinical Models</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/JNJ/johnson-johnson-acquire-ollin-biosciences</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T13:00:00.000Z</news:publication_date>
      <news:title>Johnson &amp; Johnson to acquire Ollin Biosciences and late-stage bispecific antibody with best-in-class potential in ophthalmology</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/GEHC/ge-healthcare-expands-global-collaborations-photon-counting-ct</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T13:00:00.000Z</news:publication_date>
      <news:title>GE HealthCare expands global collaborations to help define the future of photon-counting CT with Photonova™ Spectra</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/CORT/esmo-rare-cancers-relacorilant-nab-paclitaxel-vulvar-cancer</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T13:00:00.000Z</news:publication_date>
      <news:title>ESMO Rare Cancers Publishes Case Report Detailing Eight-Year Response to Relacorilant Plus Nab-Paclitaxel in Metastatic Vulvar Cancer</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/STVN/stevanato-group-investor-conferences-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T13:00:00.000Z</news:publication_date>
      <news:title>Stevanato Group to Participate in Upcoming Investor Conferences</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ADGM/adagio-medical-reports-q3-2026-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T13:00:00.000Z</news:publication_date>
      <news:title>Adagio Medical Reports Third Quarter 2026 Results</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/NUVB/nuvation-bio-safusidenib-phase-2-study-update</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T13:00:00.000Z</news:publication_date>
      <news:title>Nuvation Bio Presented Additional Long-Term Follow-Up Data from Phase 2 Study of Safusidenib in IDH1-Mutant Glioma at the 2026 Society for Neuro-Oncology Annual Meeting</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/EOCN/eocene-barcode-nanotech-aramchol-lipid-nanoparticles</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T13:00:00.000Z</news:publication_date>
      <news:title>Eocene and Barcode Nanotech Report Progress in the Development of Tumor Microenvironment-Targeted Lipid Nanoparticles Formulation of Aramchol</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/HUMA/humacyte-long-term-clinical-data-atev</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T13:00:00.000Z</news:publication_date>
      <news:title>Humacyte Presents Long-Term Clinical Data Demonstrating Low Atherosclerosis Susceptibility in Acellular Tissue Engineered Vessel</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ENLV/enlivex-7-5-million-offering-november-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T13:00:00.000Z</news:publication_date>
      <news:title>Enlivex Announces Pricing of $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ALXO/alx-oncology-q3-2026-results-corporate-update</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T13:00:00.000Z</news:publication_date>
      <news:title>ALX Oncology Reports Third Quarter 2026 Financial Results and Provides Corporate Update</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-q3-2026-financial-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T13:00:00.000Z</news:publication_date>
      <news:title>Galectin Therapeutics Reports September 30, 2026 Financial Results and Provides Business Update</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/PLUR/pluri-ceo-letter-commercial-opportunity</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T13:00:00.000Z</news:publication_date>
      <news:title>Pluri CEO Letter: Turning Our Cell Technology and Experience into Commercial Opportunity</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/MDWD/mediwound-virtual-kol-event-escharex-phase-iii-value-study</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T13:00:00.000Z</news:publication_date>
      <news:title>MediWound to Host Virtual KOL Event on EscharEx® Phase III VALUE Study and Commercial Opportunity on December 2, 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/MRNA/dr-robert-langer-joins-polaritybio-board</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T13:00:00.000Z</news:publication_date>
      <news:title>Dr. Robert Langer, Co-Founder of Moderna, Joins PolarityBio’s Board of Directors</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/INAB/in8bio-glioblastoma-data-sno-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T13:00:00.000Z</news:publication_date>
      <news:title>IN8bio Reports Updated Glioblastoma Data at SNO 2026 Demonstrating Median Overall Survival of 20.9 Months and 50% Two-Year Survival with Gamma-Delta T Cell Therapy</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-q3-2026-update</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T13:00:00.000Z</news:publication_date>
      <news:title>Neumora Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/AKBA/akebia-term-loan-symbiotic-capital-140-million</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T13:00:00.000Z</news:publication_date>
      <news:title>Akebia Enters into Term Loan Facility with Symbiotic Capital Worth Up to $140 Million</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-q3-2026-results-update</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T13:00:00.000Z</news:publication_date>
      <news:title>Jasper Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/BIVI/biovie-biomarker-data-long-covid-conference-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T13:00:00.000Z</news:publication_date>
      <news:title>BioVie Presents New Biomarker Data Highlighting Biomarker-Defined Endotypes and Neuropeptide Y Response to Bezisterim at the 4th Long COVID International Conference 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/CRBP/corbus-phase-1b-canyon-1-trial-data-obesityweek-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T13:00:00.000Z</news:publication_date>
      <news:title>Corbus Pharmaceuticals presents Phase 1b CANYON-1 clinical trial data for CRB-913 at ObesityWeek® 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-expands-phase-2-trial-ovarian-cancer</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T12:50:00.000Z</news:publication_date>
      <news:title>Allarity Therapeutics Expands Phase 2 Stenoparib Trial to Three Ovarian Cancer Patient Cohorts</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/DAVI/davion-healthcare-acquires-independence-care-network</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T12:48:00.000Z</news:publication_date>
      <news:title>Davion Healthcare Plc Agrees to Terms in Acquisition of Independence Care Homecare Network</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/RCEL/avitamedical-cohealyx-i-study-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T12:45:00.000Z</news:publication_date>
      <news:title>AVITA Medical Reports Complete Cohealyx I Data in Full-Thickness Wounds Showing Earlier Graft Readiness and Six-Month Healing Outcomes</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/CMND/clearmind-full-enrollment-part-c-cmnd-100-trial</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T12:37:00.000Z</news:publication_date>
      <news:title>Clearmind Achieves Full Enrollment for Part C in CMND-100 Phase I/IIa Trial, Marking Key Clinical Milestone</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/SPRC/scisparc-nagel-joins-scientific-advisory-board</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T12:32:00.000Z</news:publication_date>
      <news:title>SciSparc: Former National Security Advisor to Prime Minister Benjamin Netanyahu Renowned AI Prof. Jacob Nagel Joins the Company’s SAB</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/RNTX/rein-therapeutics-phase-2-renew-trial-ipf-data</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T12:30:09.000Z</news:publication_date>
      <news:title>Rein Therapeutics Announces Preliminary Blinded Phase 2 RENEW Data Showing Encouraging Lung Function Trends in Patients with Idiopathic Pulmonary Fibrosis and Reports Third Quarter 2026 Financial Results</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/CNSP/cns-pharmaceuticals-q3-2026-financial-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T12:30:00.000Z</news:publication_date>
      <news:title>CNS Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Progress in Establishing Transformative Therapeutic Pipeline</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/PTN/palatin-technologies-mc4r-peptide-agents-obesityweek-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T12:30:00.000Z</news:publication_date>
      <news:title>Palatin Technologies Presents Compelling Preclinical Data on Next-Generation MC4R-Selective Peptide Agonists at ObesityWeek® 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/SGRY/surgery-partners-consent-solicitation-senior-notes</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T12:30:00.000Z</news:publication_date>
      <news:title>Surgery Partners, Inc. Announces Commencement of Consent Solicitation Relating to Surgery Center Holdings, Inc.’s 7.250% Senior Notes due 2032</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/CNSY/cerenome-reports-respect-lm-data-reyobiq-leptomeningeal-metastases</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T12:30:00.000Z</news:publication_date>
      <news:title>Cerenome Reports Interim ReSPECT-LM Data Supporting Repeat Dosing of REYOBIQ™ in Leptomeningeal Metastases at the 2026 SNO Annual Meeting</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/MDCX/medicus-pharma-closes-equity-financing-debt-exchange</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T12:30:00.000Z</news:publication_date>
      <news:title>Medicus Pharma Announces Closing of $4.25 Million CEO-Led Equity Financings and $10.5 Million Debt Exchange</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/MBRX/moleculin-biotech-q3-2026-results-miracle-trial-update</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T12:30:00.000Z</news:publication_date>
      <news:title>Moleculin Biotech Reports Third Quarter 2026 Financial Results as Pivotal MIRACLE Trial Advances Toward Key Q1 2027 Data Readout</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/AZN/baxfendy-approval-eu-hypertension</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T12:21:03.000Z</news:publication_date>
      <news:title>Baxfendy (baxdrostat) recommended for approval in the EU for the treatment of adults with hypertension</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-third-quarter-2026-update</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T12:15:00.000Z</news:publication_date>
      <news:title>Larimar Therapeutics Reports Third Quarter 2026 Financial and Business Update</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/MPLT/maplight-therapeutics-q3-2026-results-update</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T12:15:00.000Z</news:publication_date>
      <news:title>MapLight Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/NGEN/nervgen-third-quarter-2026-financial-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T12:15:00.000Z</news:publication_date>
      <news:title>NervGen Reports Third Quarter 2026 Financial Results and Provides Business Updates</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/AZN/imfinzi-approved-neoadjuvant-enfortumab-bladder-cancer</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T12:13:23.000Z</news:publication_date>
      <news:title>Perioperative Imfinzi approved in the US in novel regimen with neoadjuvant enfortumab vedotin for patients with muscle-invasive bladder cancer</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/UNCY/unicycive-therapeutics-q3-2026-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T12:05:00.000Z</news:publication_date>
      <news:title>Unicycive Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/AZN/klygefa-approval-generalized-myasthenia-gravis</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T12:01:44.000Z</news:publication_date>
      <news:title>Klygefa (gefurulimab) approved in the US for the treatment of generalised myasthenia gravis (gMG) in adult patients</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/IVVD/invivyd-reports-q3-2026-results-and-business-highlights</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T12:01:00.000Z</news:publication_date>
      <news:title>Invivyd Reports Third Quarter 2026 Financial Results and Recent Business Highlights</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-q3-2026-financial-results-update</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T12:01:00.000Z</news:publication_date>
      <news:title>Prelude Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/MGTX/meiragtx-oral-presentation-obesityweek-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T12:00:31.000Z</news:publication_date>
      <news:title>MeiraGTx Announces Oral Presentation at ObesityWeek 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/TTRX/turn-therapeutics-jefferies-conference-london</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T12:00:00.000Z</news:publication_date>
      <news:title>Turn Therapeutics to Present at Jefferies Global Healthcare Conference in London</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/BRKR/bruker-dr-eicke-latz-board-directors</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T12:00:00.000Z</news:publication_date>
      <news:title>Bruker Announces that Institute Director, Biopharma Entrepreneur and Immunology Leader Dr. Eicke Latz will join its Board of Directors</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/FTH/faeth-therapeutics-roche-clinical-trial-collaboration</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T12:00:00.000Z</news:publication_date>
      <news:title>Faeth Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate PIKTOR in Combination with a Selective Estrogen Receptor Degrader in HR+/HER2- Advanced Breast Cancer</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ELOX/eloxx-pharmaceuticals-q3-2026-results-update</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T12:00:00.000Z</news:publication_date>
      <news:title>Eloxx Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/XTNT/xtant-medical-q3-2026-financial-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T12:00:00.000Z</news:publication_date>
      <news:title>Xtant Medical Reports Third Quarter 2026 Financial Results and Announces Board-led Strategic Review Process</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/BLRX/biolinerx-hemispherian-glix1-sno-2026-updates</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T12:00:00.000Z</news:publication_date>
      <news:title>BioLineRx and Hemispherian Present Phase 1/2a Clinical Study and Pre-Clinical Updates, Including Brain PK/PD Data, at SNO 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/HELP/helus-pharma-approach-study-hlp003-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T12:00:00.000Z</news:publication_date>
      <news:title>Helus Pharma Announces Positive Topline Results from Phase 3 APPROACH Study evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-fda-fast-track-onvansertib</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T12:00:00.000Z</news:publication_date>
      <news:title>Cardiff Oncology Receives FDA Fast Track Designation for Onvansertib in First-Line RAS-Mutated Metastatic Colorectal Cancer</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-positive-phase-i-ii-data-lx2020</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T12:00:00.000Z</news:publication_date>
      <news:title>Lexeo Therapeutics Announces Positive Interim Phase I/II Data and Regulatory Update for LX2020 in PKP2 Arrhythmogenic Cardiomyopathy and Reports Third Quarter 2026 Financial Results</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/TIL/instil-bio-reports-q3-2026-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T12:00:00.000Z</news:publication_date>
      <news:title>Instil Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/LMRI/lumexa-imaging-opens-new-imaging-centers-november</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T12:00:00.000Z</news:publication_date>
      <news:title>Lumexa Imaging Opens Three New Imaging Centers in November</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/GTBP/gt-biopharma-reports-q3-2026-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T12:00:00.000Z</news:publication_date>
      <news:title>GT Biopharma Reports Third Quarter 2026 Financial Results</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/MDLN/medline-inc-announces-launch-secondary-offering-class-common-stock-20261116</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T11:53:00.000Z</news:publication_date>
      <news:title>Medline Inc. announces launch of secondary offering of Class A common stock</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/AZN/klygefa-approved-eu-generalised-myasthenia-gravis</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T11:52:23.000Z</news:publication_date>
      <news:title>Klygefa (gefurulimab) approved in the EU for the treatment of adults with generalised myasthenia gravis (gMG)</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/MDT/medtronic-acquire-contego-medical-carotid-therapies</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T11:45:00.000Z</news:publication_date>
      <news:title>Medtronic to acquire Contego Medical, expanding access to next-generation carotid therapies</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/HKPD/cellyan-biotechnology-regains-nasdaq-compliance</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T11:40:00.000Z</news:publication_date>
      <news:title>CELLYAN BIOTECHNOLOGY CO., LTD REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/OSCR/oscar-health-board-expansion-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T11:00:00.000Z</news:publication_date>
      <news:title>Oscar Health Expands its Board of Directors with Technology, Healthcare and Product Innovators to Advance Consumer Healthcare</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/HSIC/henry-schein-updates-non-gaap-financial-measures</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T11:00:00.000Z</news:publication_date>
      <news:title>Henry Schein Updates Presentation of Non-GAAP Financial Measures</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/HELP/helus-pharma-q2-fiscal-2027-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T11:00:00.000Z</news:publication_date>
      <news:title>Helus Pharma Reports Second Quarter Fiscal 2027 Financial Results and Recent Business Highlights</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/AVR/anteris-duravr-thv-one-year-outcomes-pcr-london-valves</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T11:00:00.000Z</news:publication_date>
      <news:title>Anteris Announces Late-Breaking PCR London Valves Data Release: One-Year DurAVR THV Outcomes in 100 Patients</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ZYME/zymeworks-share-repurchase-authorization</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T11:00:00.000Z</news:publication_date>
      <news:title>Zymeworks Announces $200 Million Share Repurchase Authorization</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/KMTS/kestra-ace-pas-wearable-defibrillator-study</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T11:00:00.000Z</news:publication_date>
      <news:title>Kestra Announces Publication of ACE-PAS, the Largest Prospective Real-World Wearable Defibrillator Study, in the Journal of Cardiovascular Electrophysiology</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ALMR/alamar-biosciences-nulisa-data-ctad-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T11:00:00.000Z</news:publication_date>
      <news:title>Alamar Biosciences Highlights NULISA Data in 46 Presentations at CTAD 2026, Including 10 Oral Presentations</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/VANI/vivani-medical-private-placement-financing</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T10:30:00.000Z</news:publication_date>
      <news:title>Vivani Medical Announces Private Placement Equity Financing</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/CYTK/cytokinetics-myqorzo-prescribing-information-update</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T09:00:00.000Z</news:publication_date>
      <news:title>Cytokinetics Announces Prescribing Information for MYQORZO® (aficamten) Expanded to Include Data from Phase 3 MAPLE-HCM</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ACRS/aclaris-phase-2b-trial-modzatinib-lichen-planus</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T08:30:00.000Z</news:publication_date>
      <news:title>Aclaris Therapeutics Initiates Phase 2b Trial of Modzatinib (ATI-2138) in Lichen Planus (LP)</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ACRS/aclaris-phase-2-results-bosakitug-atopic-dermatitis</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T08:28:00.000Z</news:publication_date>
      <news:title>Aclaris Therapeutics Announces Top Line Phase 2 Results for its Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) in Atopic Dermatitis (AD)</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/PHG/philips-nominates-new-supervisory-board-members-2027-agm</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T07:30:00.000Z</news:publication_date>
      <news:title>Philips to nominate Dick Boer, Laurence Debroux and Todd Brinton to its Supervisory Board at the 2027 Annual General Meeting of Shareholders (AGM)</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/blog/biotech-catalysts-to-watch-week-of-2026-11-16</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T07:15:54.444Z</news:publication_date>
      <news:title>Troculeucel Phase 1: Biotech Catalysts Nov 16, 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-appoints-uro-oncology-leader</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T07:00:00.000Z</news:publication_date>
      <news:title>Relmada Therapeutics Appoints Uro-Oncology Leader Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/OCS/oculis-fda-ind-clearance-privosegtor-ms-relapses</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T07:00:00.000Z</news:publication_date>
      <news:title>Oculis Announces FDA IND Clearance Enabling Acceleration of Privosegtor Development Program in Acute Multiple Sclerosis Relapses</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/EVO/evotec-secures-grant-drug-safety-testing</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T06:57:00.000Z</news:publication_date>
      <news:title>Evotec Secures $2.9 Million Grant to Advance Early Drug Safety Testing Using Human Stem Cell Technology</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/LKFT/lakefront-new-share-repurchase-program</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T06:30:00.000Z</news:publication_date>
      <news:title>Lakefront Initiates New €50 Million Share Repurchase Program Following Completion of Initial Share Repurchase Program</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/HCM/hutchmed-expanded-coverage-nrdl-elunate-orpathys</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T04:00:00.000Z</news:publication_date>
      <news:title>HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List for ELUNATE® and ORPATHYS®</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-lisaftoclax-olverembatinib-nrdl-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-15T23:30:00.000Z</news:publication_date>
      <news:title>Ascentage Pharma Announces Inclusion of Lisaftoclax in China&apos;s 2026 National Reimbursement Drug List and Successful Renewal of Coverage for Olverembatinib</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/MESO/mesoblast-asx-investor-day-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-15T23:16:00.000Z</news:publication_date>
      <news:title>Mesoblast Showcased at ASX Premier Investor Day Event</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-nominates-ide101-candidate</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-15T20:00:00.000Z</news:publication_date>
      <news:title>IDEAYA Biosciences Announces Development Candidate Nomination of IDE101, a Potential First-In-Class Inhibitor Targeting CDKN2A-Deficiency in Solid Tumors</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/DRTS/alpha-dart-recurrent-glioblastoma-trial-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-15T18:00:00.000Z</news:publication_date>
      <news:title>New Positive Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial: All Patients Treated are Alive with Median Survival Not Reached, 6.9 Months Median Follow-Up in the First Six Evaluable Patients With 100% ORR, 100% Feasibility and No Unanticipated Serious Adverse Events – Conference Call Scheduled for 8:30am ET November 16</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-vk2735-obesity-week-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-15T17:05:00.000Z</news:publication_date>
      <news:title>Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program at ObesityWeek® 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/HELP/helus-pharma-phase-3-approach-study-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-15T17:00:00.000Z</news:publication_date>
      <news:title>Helus Pharma to Present Topline Results from Phase 3 APPROACH Study Evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder on November 16, 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/CVS/cvs-health-glp-1-benefits-affordability-challenge</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-15T15:00:00.000Z</news:publication_date>
      <news:title>CVS Health study highlights GLP-1 benefits and the affordability challenge</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-q3-2026-results-update</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-15T12:00:00.000Z</news:publication_date>
      <news:title>Lexeo Therapeutics to Report Third Quarter 2026 Financial Results and Provide LX2020 Business Update on November 16, 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-ivonescimab-update</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-15T12:00:00.000Z</news:publication_date>
      <news:title>Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-business-update-q3-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-15T12:00:00.000Z</news:publication_date>
      <news:title>Cocrystal Pharma Provides Business Update and Reports Third Quarter 2026 Financial Results</news:title>
    </news:news>
  </url>
</urlset>